Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

In contrast, JPMorgan's competitor Wells Fargo (NYSE: WFC) has risen by 6% over the same duration. So, what has contributed to the strong performance of JPMorgan stock?

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

The Motley Fool dove into the financial sector and reported on the world's largest financial companies by market cap. JPMorgan Chase (JPM -0.33%) checked in at No. 2, after Berkshire Hathaway.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data.